HIMS250509C31500
- 11.20
- +1.06+10.45%
Hims & Hers Health Newsroom
Piper Sandler Maintains Hims & Hers Health(HIMS.US) With Hold Rating, Raises Target Price to $35
BofA Securities Maintains Hims & Hers Health(HIMS.US) With Sell Rating, Raises Target Price to $26
Sell Rating Maintained for Hims & Hers Health Amid Market Concerns Despite Strategic Partnership With Novo Nordisk
TD Cowen Downgrades Hims & Hers Health(HIMS.US) to Hold Rating, Raises Target Price to $30
Citi Maintains Hims & Hers Health(HIMS.US) With Sell Rating, Maintains Target Price $25
Morgan Stanley Maintains Hims & Hers Health(HIMS.US) With Hold Rating, Cuts Target Price to $40
Hims & Hers Health Is Maintained at Equal-Weight by Morgan Stanley
Hims & Hers Health Analyst Ratings
Hold Rating on Hims & Hers Health: Limited Near-Term Catalysts Amid Economic Challenges
Truist Financial Maintains Hims & Hers Health(HIMS.US) With Hold Rating
Needham Maintains Hims & Hers Health(HIMS.US) With Buy Rating, Cuts Target Price to $31
Analysts Offer Insights on Healthcare Companies: Centene (CNC), CareCloud (CCLD) and Hims & Hers Health (HIMS)
Hims & Hers Health Is Maintained at Sell by Citigroup
Hims & Hers Health Analyst Ratings
BofA Securities Maintains Hims & Hers Health(HIMS.US) With Sell Rating, Maintains Target Price $22
Sell Rating Issued for Hims & Hers Health Amid FDA Concerns on Topical Finasteride
BofA Securities Maintains Hims & Hers Health(HIMS.US) With Sell Rating, Maintains Target Price $22
Sell Rating for Hims & Hers Health Due to Slowing Sales Growth and Regulatory Risks
Truist Financial Maintains Hims & Hers Health(HIMS.US) With Hold Rating, Announces Target Price $33
Hims & Hers Health Is Maintained at Hold by Truist Securities